The 10th CVOT Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes provided an interactive and multidisciplinary platform to discuss key results from recently published trials with SGLT2i (EMPACT-MI), GLP-1 RA (STEP-HFpEF-DM and FLOW), dual GIP/GLP-1 RA (SUMMIT and SURMOUNT-OSA) and nsMRA (FINEARTS-HF). This evidence concerns the gene GIP and obstructive sleep apnea syndrome.